These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32146028)

  • 21. Sustained effects of single doses of classical psychedelics in humans.
    Knudsen GM
    Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.
    Smigielski L; Kometer M; Scheidegger M; Krähenmann R; Huber T; Vollenweider FX
    Sci Rep; 2019 Oct; 9(1):14914. PubMed ID: 31649304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.
    Jalal B
    Psychopharmacology (Berl); 2018 Nov; 235(11):3083-3091. PubMed ID: 30288594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
    Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
    Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications.
    Shahar O; Botvinnik A; Esh-Zuntz N; Brownstien M; Wolf R; Lotan A; Wolf G; Lerer B; Lifschytz T
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.
    Hesselgrave N; Troppoli TA; Wulff AB; Cole AB; Thompson SM
    Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33850049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain.
    Yang KC; Stepanov V; Martinsson S; Ettrup A; Takano A; Knudsen GM; Halldin C; Farde L; Finnema SJ
    Int J Neuropsychopharmacol; 2017 Sep; 20(9):683-691. PubMed ID: 28911007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression.
    Lyons T; Carhart-Harris RL
    J Psychopharmacol; 2018 Jul; 32(7):811-819. PubMed ID: 29338538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 'PSILAUT' protocol: an experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin.
    Whelan TP; Daly E; Puts NA; Smith P; Allison C; Baron-Cohen S; Malievskaia E; Murphy DGM; McAlonan GM
    BMC Psychiatry; 2024 Apr; 24(1):319. PubMed ID: 38658877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
    Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
    Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36.
    Ettrup A; da Cunha-Bang S; McMahon B; Lehel S; Dyssegaard A; Skibsted AW; Jørgensen LM; Hansen M; Baandrup AO; Bache S; Svarer C; Kristensen JL; Gillings N; Madsen J; Knudsen GM
    J Cereb Blood Flow Metab; 2014 Jul; 34(7):1188-96. PubMed ID: 24780897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based discovery of nonhallucinogenic psychedelic analogs.
    Cao D; Yu J; Wang H; Luo Z; Liu X; He L; Qi J; Fan L; Tang L; Chen Z; Li J; Cheng J; Wang S
    Science; 2022 Jan; 375(6579):403-411. PubMed ID: 35084960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychedelics as anti-inflammatory agents.
    Flanagan TW; Nichols CD
    Int Rev Psychiatry; 2018 Aug; 30(4):363-375. PubMed ID: 30102081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
    Rucker JJ; Marwood L; Ajantaival RJ; Bird C; Eriksson H; Harrison J; Lennard-Jones M; Mistry S; Saldarini F; Stansfield S; Tai SJ; Williams S; Weston N; Malievskaia E; Young AH
    J Psychopharmacol; 2022 Jan; 36(1):114-125. PubMed ID: 35090363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.
    Kometer M; Schmidt A; Bachmann R; Studerus E; Seifritz E; Vollenweider FX
    Biol Psychiatry; 2012 Dec; 72(11):898-906. PubMed ID: 22578254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.
    Lewis CR; Preller KH; Kraehenmann R; Michels L; Staempfli P; Vollenweider FX
    Neuroimage; 2017 Oct; 159():70-78. PubMed ID: 28711736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.
    Vollenweider FX; Vontobel P; Hell D; Leenders KL
    Neuropsychopharmacology; 1999 May; 20(5):424-33. PubMed ID: 10192823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multimodal brain age prediction using machine learning: combining structural MRI and 5-HT2AR PET-derived features.
    Dörfel RP; Arenas-Gomez JM; Svarer C; Ganz M; Knudsen GM; Svensson JE; Plavén-Sigray P
    Geroscience; 2024 Oct; 46(5):4123-4133. PubMed ID: 38668887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.